Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

Efficacy and Safety of Phentermine/Topiramate in Youth and Young Adults with Hypothalamic Obesity

HOPTop

Phase: II
Clinicaltrials.gov ID: NCT06299891

What is the goal of the study?

The purpose of this study is to evaluate how safe and effective the drug Qsymia (Phentermine/Topiramate or Ph/T) is for children, adolescents, and young adults with hypothalamic obesity. We will also evaluate if Ph/T helps with weight loss and changes in hunger in patients with hypothalamic obesity. Qsymia is FDA approved to treat adults with obesity (BMI of 30 kg/m2 or greater) and pediatric patients, aged 12 and older, with obesity (BMI in 95th %ile or greater).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Christian Roth
Study Team Member: ECR Endocrine Research, [email protected]

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.